Serum concentrations of sCD30 and sCD40L in patients with malignant bone tumours

Wiener Medizinische Wochenschrift

Volumn 153, Issue 1-2, 2003, Pages 40-42

  Holzer, Gerold ^a   Pfandlsteiner, Thomas ^a   Blahovec, Harald ^a   Trieb, Klemens ^a   Kotz, Rainer ^a  

^a Department of Orthopaedics ^*  (Austria)

Author keywords

Ewing sarcoma; High grade osteosarcoma; sCD30; sCD40L; Serum concentrations

Indexed keywords

CD30 ANTIGEN; CD40 LIGAND; TUMOR MARKER;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE TUMOR; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EWING SARCOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; OSTEOSARCOMA; SCHOOL CHILD; STATISTICAL ANALYSIS;

EID: 0037262898     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-258X.2003.02008.x     Document Type: Article

References (19)

1. Biehling B, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielak S, Heis U, Jürgens H, Treuner J, Romanowsky R, Exner U, Kotz R, Winkler K: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848-858.
2. Clodi K, Asgary Z, Zhao S, Kliche KO, Cabanillas F, Andreeff M, Younes A: Coexpression of CD40 and CD40L in B-cell lymphoma cells. Br J Haematol 1998;103:270-275.
3. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcomas. Clin Orthop 1980;153:106-120.
4. Gerli R, Muscat C, Bistoni O, Falini B, Tomassini C, Agea E, Tognellini R, Biagini P, Bertotto A: High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995;102:547-550.
5. Gerli R, Bistoni O, Lunardi C, Giacomelli R, Tomassini C, Biagini P, Pitzalis C: Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy. Rheumatol 1999;38:1282-1284.
6. Gerli R, Pitzalis C, Bistoni O, Falini B, Constantini V, Russano A, Lunardi C: CD30+ T cells in Rheumatoid Synovitis: Mechanisms of recruitment and functional role. J Immunol 2000;164:4399-4407.
7. Hansen Hinrich P, Kisselva T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H: A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 1995;63:750-756.
8. Iwagaki H, Hizuta A, Kohka H, Kobashi K, Nitta Y, Isozaki H, Takakura N, Tanaka N: Circulating levels of soluble CD30 and other markers in colorectal cancer patients. J Med 1999;30:111-121.
9. Josimovic-Alasevic O, Durkop H., Schwarting R., et al. Ki-1 (CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo. First partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme linked immunosorbent assay. Eur J Immunol 1989;19:157-162.
10. Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, McConell F: Soluble CD40L can replace the normal T-cell derived CD40L signal to B cells in T cell dependent activation. J Exp Med 1993;177:1209-1213.
11. Lollini PL, Landuzzi L, Frabetti F, Rossi I, Nicoletti G, Scotlandi K, Serra M, Baldini N, De Giovanni C, Nanni P: Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin Cancer Res 1998;4:1843-1849.
12. Mechtersheimer G, Möller P: Expression of Ki-1 (CD30) antigen in mesenchymal tumors. Cancer 1990;66:1732-1737.
13. Meyers PA, Gorlick R: Osteosarcoma. Pedriatr Clin North Am 1997;44:973-989.
14. Nadali G, Vinante F, Stein H, Todeschini G, Tecchio C, Morosato L, Chilosi M, Menestrina F, Kinney MC, Greer JP: Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol 1995;13:1355-1360.
15. Paulussen M, Ahrens S, Braun-Munzinger G, Craft AW, Dockhorn-Dworniczak B, Dorffel W, Dunst J, Fohlich B, Gobel U, Haussler M, Klingebiel T, Koscielniak E, Mittler U, Rube C, Winkelmann W, Voute PA, Zoubek A, Jurgens H: EICESS 92-European Intergroup Cooperative Ewing's Sarcoma Study. Klin-Pädiatr 1999;211:276-283.
16. Pfreundschuh M, Pohl C, Berenbeck C, Schroeder J, Jung W, Schmits R, Tschiersch A, Diehl V, Gause A: Detection of a soluble form of the CD30 antigen in sera of patients with Lymphoma, Adult T-cell Leukemia and Infectious Mononucleosis. Int J Cancer 1990;45:869-874.
17. Salzer-Kuntschik M, Brand G, Delling G: Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe 1983;4:135.
18. Trieb K, Kotz R: Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol 2001;33:11-17.
19. Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK, Armitage RJ, Andreeff M: Elevated levels of biologically active soluble CD40L in the serum of patients with chronic lymphocytic leukemia. Br J Haematol 1998;100:135-141.